Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EG3N
|
|||
| Drug Name |
1,2-diamino cyclopentane-based derivative 34
|
|||
| Synonyms |
PMID26593218-Compound-55
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H19FN6OS
|
|||
| Canonical SMILES |
C1CC(C(C1)NC(=O)C2=C(C=CC=N2)N3C=CC=N3)NC4=NC5=C(S4)C=C(C=C5)F
|
|||
| InChI |
1S/C21H19FN6OS/c22-13-7-8-16-18(12-13)30-21(27-16)26-15-5-1-4-14(15)25-20(29)19-17(6-2-9-23-19)28-11-3-10-24-28/h2-3,6-12,14-15H,1,4-5H2,(H,25,29)(H,26,27)/t14-,15-/m0/s1
|
|||
| InChIKey |
ZNHYIIOVQSLYRA-GJZGRUSLSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Orexin receptor type 1 (HCRTR1) | Target Info | Antagonist | [1] |
| Orexin receptor type 2 (HCRTR2) | Target Info | Antagonist | [1] | |
| Target's Patent Info | Orexin receptor type 1 (HCRTR1) | Target's Patent Info | [1] | |
| Orexin receptor type 2 (HCRTR2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | G alpha (q) signalling events | |||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.